• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物组与肝脏疾病的相互作用。

Interactions between the intestinal microbiome and liver diseases.

机构信息

Department of Medicine, University of California San Diego, La Jolla, California.

Department of Medicine, University of California San Diego, La Jolla, California.

出版信息

Gastroenterology. 2014 May;146(6):1513-24. doi: 10.1053/j.gastro.2014.01.020. Epub 2014 Jan 15.

DOI:10.1053/j.gastro.2014.01.020
PMID:24440671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3996054/
Abstract

The human intestine harbors a diverse community of microbes that promote metabolism and digestion in their symbiotic relationship with the host. Disturbance of its homeostasis can result in disease. We review factors that disrupt intestinal homeostasis and contribute to nonalcoholic fatty liver disease, steatohepatitis, alcoholic liver disease, and cirrhosis. Liver disease has long been associated with qualitative and quantitative (overgrowth) dysbiotic changes in the intestinal microbiota. Extrinsic factors, such as the Western diet and alcohol, contribute to these changes. Dysbiosis results in intestinal inflammation, a breakdown of the intestinal barrier, and translocation of microbial products in animal models. However, the contribution of the intestinal microbiome to liver disease goes beyond simple translocation of bacterial products that promote hepatic injury and inflammation. Microbial metabolites produced in a dysbiotic intestinal environment and host factors are equally important in the pathogenesis of liver disease. We review how the combination of liver insult and disruptions in intestinal homeostasis contribute to liver disease.

摘要

人类肠道中栖息着多样化的微生物群落,它们与宿主共生,促进新陈代谢和消化。其体内平衡的破坏可导致疾病。我们综述了破坏肠道内环境稳态并导致非酒精性脂肪性肝病、脂肪性肝炎、酒精性肝病和肝硬化的因素。长期以来,肝脏疾病与肠道微生物群落的定性和定量(过度生长)失调变化相关联。外在因素,如西方饮食和酒精,促成了这些变化。肠道菌群失调导致肠道炎症、肠道屏障破坏和微生物产物易位。然而,肠道微生物组对肝脏疾病的影响不仅仅是简单的细菌产物易位,这些产物会促进肝损伤和炎症。在失调的肠道环境中产生的微生物代谢产物和宿主因素在肝脏疾病的发病机制中同样重要。我们综述了肝损伤和肠道内环境稳态破坏的共同作用如何导致肝脏疾病。

相似文献

1
Interactions between the intestinal microbiome and liver diseases.肠道微生物组与肝脏疾病的相互作用。
Gastroenterology. 2014 May;146(6):1513-24. doi: 10.1053/j.gastro.2014.01.020. Epub 2014 Jan 15.
2
Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.补充饱和长链脂肪酸可维持小鼠肠道微生态平衡并减轻乙醇诱导的肝损伤。
Gastroenterology. 2015 Jan;148(1):203-214.e16. doi: 10.1053/j.gastro.2014.09.014. Epub 2014 Sep 16.
3
The gut-liver axis in liver disease: Pathophysiological basis for therapy.肝脏疾病中的肠-肝轴:治疗的病理生理学基础。
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
4
Gut microbiota and host metabolism in liver cirrhosis.肝硬化中的肠道微生物群与宿主代谢
World J Gastroenterol. 2015 Nov 7;21(41):11597-608. doi: 10.3748/wjg.v21.i41.11597.
5
Role of gut microbiota in liver disease.肠道微生物群在肝脏疾病中的作用。
Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1;318(1):G84-G98. doi: 10.1152/ajpgi.00118.2019. Epub 2019 Oct 28.
6
Linking intestinal homeostasis and liver disease.连接肠道内稳态与肝脏疾病。
Curr Opin Gastroenterol. 2013 May;29(3):264-70. doi: 10.1097/MOG.0b013e32835ff948.
7
Host-microbiome interactions in alcoholic liver disease.宿主-微生物组在酒精性肝病中的相互作用。
Gut Liver. 2014 May;8(3):237-41. doi: 10.5009/gnl.2014.8.3.237.
8
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.肠-肝轴、肝硬化和门静脉高压:先有鸡还是先有蛋。
Hepatol Int. 2018 Feb;12(Suppl 1):24-33. doi: 10.1007/s12072-017-9798-x. Epub 2017 May 26.
9
The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.肠道微生物群作为治疗非酒精性脂肪性肝病和酒精性肝病的治疗靶点。
Biomed Pharmacother. 2021 Mar;135:111235. doi: 10.1016/j.biopha.2021.111235. Epub 2021 Feb 6.
10
Alcohol or Gut Microbiota: Who Is the Guilty?酒精还是肠道微生物群:谁是罪魁祸首?
Int J Mol Sci. 2019 Sep 14;20(18):4568. doi: 10.3390/ijms20184568.

引用本文的文献

1
Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies.探索代谢功能障碍相关脂肪性肝病与肠道菌群失调之间的相互作用:病理生理学、临床意义及新兴疗法。
World J Hepatol. 2025 Aug 27;17(8):108730. doi: 10.4254/wjh.v17.i8.108730.
2
Safety and efficacy of probiotics in the treatment of ALD.益生菌治疗酒精性肝病的安全性和有效性。
Medicine (Baltimore). 2025 Aug 8;104(32):e43662. doi: 10.1097/MD.0000000000043662.
3
Bibliometric and Visualized Analysis of Gut Microbiota and Hypertension Interaction Research Published from 2001 to 2024.

本文引用的文献

1
Pathological bacterial translocation in liver cirrhosis.肝硬化中的病理性细菌移位
J Hepatol. 2014 Jan;60(1):197-209. doi: 10.1016/j.jhep.2013.07.044. Epub 2013 Aug 28.
2
Ethanol metabolism and its effects on the intestinal epithelial barrier.乙醇代谢及其对肠道上皮屏障的影响。
Nutr Rev. 2013 Jul;71(7):483-99. doi: 10.1111/nure.12027. Epub 2013 May 6.
3
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.法尼醇 X 受体激动剂奥贝胆酸治疗 2 型糖尿病合并非酒精性脂肪性肝病患者的疗效和安全性。
2001年至2024年发表的肠道微生物群与高血压相互作用研究的文献计量学和可视化分析
Microorganisms. 2025 Jul 18;13(7):1696. doi: 10.3390/microorganisms13071696.
4
The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure.细菌外膜囊泡在慢加急性肝衰竭炎症反应中的作用
Front Microbiol. 2025 Jul 4;16:1608137. doi: 10.3389/fmicb.2025.1608137. eCollection 2025.
5
Small Intestinal Bacterial Overgrowth in Patients With Severe Alcoholic Hepatitis: Frequency and Predictors.重症酒精性肝炎患者的小肠细菌过度生长:发生率及预测因素
Cureus. 2025 Jun 7;17(6):e85516. doi: 10.7759/cureus.85516. eCollection 2025 Jun.
6
Targeting gut health: Probiotics as promising therapeutics in alcohol-related liver disease management.针对肠道健康:益生菌作为酒精性肝病管理中有前景的治疗方法。
AIMS Microbiol. 2025 Jun 11;11(2):410-435. doi: 10.3934/microbiol.2025019. eCollection 2025.
7
Unlocking therapeutic potential of amlexanox in MASH with insights into bile acid metabolism and microbiome.通过深入了解胆汁酸代谢和微生物群来挖掘氨来呫诺在非酒精性脂肪性肝炎中的治疗潜力。
NPJ Gut Liver. 2025;2. doi: 10.1038/s44355-024-00015-7. Epub 2025 Feb 1.
8
An In Vitro Gut-Liver-Adipose Axis Model to Evaluate the Anti-Obesity Potential of a Novel Probiotic-Polycosanol Combination.一种用于评估新型益生菌-多廿烷醇组合抗肥胖潜力的体外肠-肝-脂肪轴模型
Foods. 2025 Jun 5;14(11):2003. doi: 10.3390/foods14112003.
9
Interacting roles of gut microbiota and T cells in the development of autoimmune hepatitis.肠道微生物群与T细胞在自身免疫性肝炎发展中的相互作用
Front Immunol. 2025 May 26;16:1584001. doi: 10.3389/fimmu.2025.1584001. eCollection 2025.
10
Effects of Dairy Matrix on the Intestinal, Liver, and Bone Transcriptome of Healthy Rats.乳制品基质对健康大鼠肠道、肝脏和骨骼转录组的影响。
Foods. 2025 Apr 16;14(8):1375. doi: 10.3390/foods14081375.
Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30.
4
Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption.慢性乙醇摄入诱导大鼠胆汁酸代谢改变。
FASEB J. 2013 Sep;27(9):3583-93. doi: 10.1096/fj.13-231860. Epub 2013 May 24.
5
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.肠道微生物对磷脂酰胆碱的代谢与心血管风险
N Engl J Med. 2013 Apr 25;368(17):1575-84. doi: 10.1056/NEJMoa1109400.
6
Linking intestinal homeostasis and liver disease.连接肠道内稳态与肝脏疾病。
Curr Opin Gastroenterol. 2013 May;29(3):264-70. doi: 10.1097/MOG.0b013e32835ff948.
7
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease.非酒精性脂肪性肝病肥胖患者的粪便微生物组和挥发性有机化合物代谢组。
Clin Gastroenterol Hepatol. 2013 Jul;11(7):868-75.e1-3. doi: 10.1016/j.cgh.2013.02.015. Epub 2013 Feb 27.
8
Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice.肠黏蛋白-2 缺乏可改善小鼠实验性酒精性肝病。
Hepatology. 2013 Jul;58(1):108-19. doi: 10.1002/hep.26321. Epub 2013 May 27.
9
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function.肝硬化患者激活的肠道巨噬细胞释放的 NO 和 IL-6 可能破坏肠道屏障功能。
J Hepatol. 2013 Jun;58(6):1125-32. doi: 10.1016/j.jhep.2013.01.038. Epub 2013 Feb 9.
10
Intestinal microbiota in patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者的肠道微生物群。
Hepatology. 2013 Jul;58(1):120-7. doi: 10.1002/hep.26319. Epub 2013 May 14.